Envudeucitinib clinical trials
Also written ESK-001.
How each study uses envudeucitinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2022 (3)
| Year | Studies |
|---|---|
| 2022 | 3 |
| 2023 | 3 |
| 2024 | 3 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 11 · Other 0
Alumis Inc (11)
Related medicines
As reviewed, each with the page that says it.
- One of JAK inhibitors source
- One of Protein Kinase Inhibitors source
- One of Tyrosine kinase inhibitors (TKIs) source
Studies
Open first, then newest update. How each study uses envudeucitinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 11
- A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque PsoriasisCompletedPhase 3Alumis IncNCT06586112Written as Envudeucitinib
- A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001CompletedPhase 3Alumis IncNCT06588738Written as Envudeucitinib
- Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque PsoriasisActive, not recruitingPhase 2Alumis IncNCT05739435Written as envudeucitinib
- Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus ErythematosusActive, not recruitingPhase 2Alumis IncNCT05966480Written as Envudeucitinib
- An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver DamageCompletedPhase 1Alumis IncNCT06952634Written as envudeucitinib
- An Investigational Study to Evaluate the Cardiac Safety Assessment (TQTc Study) of ESK-001CompletedPhase 1Alumis IncNCT07378579Written as ESK-001
- An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Impaired Renal FunctionCompletedPhase 1Alumis IncNCT06962774Written as ESK-001
- A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque PsoriasisCompletedPhase 2Alumis IncNCT05600036Written as ESK-001
- POC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIUTerminatedPhase 2Alumis IncNCT05953688Written as ESK-001
- Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy ParticipantsCompletedPhase 1Alumis IncNCT05330858Written as ESK-001
- Multiple Dose Study to Determine Safety and Tolerability of ESK-001 in Healthy ParticipantsCompletedPhase 1Alumis IncNCT05431634Written as Experimental drug: ESK-001
Codes
What other systems call envudeucitinib · ClinicalTrials.gg INT017053
- UNII (FDA) KD2MDJ4GABENVUDEUCITINIBOne source FDA
- NCI Thesaurus C206909EnvudeucitinibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | KD2MDJ4GAB | ENVUDEUCITINIB | One source FDA |
| NCI Thesaurus | C206909 | Envudeucitinib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.